79762-54-2

Basic information

• Product Name: 6-Bromoindazole
• Synonyms: 6-BROMOINDAZOLE;1H-Indazole, 6-bromo-;6-Bromo-1H-indazole;6-Bromo-1H-indazole 95%;IFLAB-BB F2108-0126;6-BROMO-1H-INDAZOLE
• CAS NO: 79762-54-2
• Molecular Formula: C₇H₅BrN₂
• Molecular Weight: 197.03
• EINECS: 1312995-182-4
• Product Categories: pharmacetical;Indazole;CHIRAL CHEMICALS;Fused Ring Systems;Halides;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building BlocksHeterocyclic Building Blocks;Indazoles;New Products for Chemical Synthesis;Building Blocks;Chemical Synthesis;Halogenated Heterocycles;Heterocyclic Building Blocks
• Mol File: 79762-54-2.mol
• Article Data: 22

Chemical Properties

• Melting Point: 180-182
• Boiling Point: 333.821 °C at 760 mmHg
• Flash Point: 155.69 °C
• Appearance: /
• Density: 1.771 g/cm³
• Storage Temp.: Sealed in dry,Room Temperature
• Solubility: soluble in Methanol
• PKA: 12.78±0.40(Predicted)
• CAS DataBase Reference: 6-Bromoindazole(CAS DataBase Reference)
• NIST Chemistry Reference: 6-Bromoindazole(79762-54-2)
• EPA Substance Registry System: 6-Bromoindazole(79762-54-2)

Safety Data

• Hazard Codes: Xi,Xn
• Statements: 22-41
• Safety Statements: 26-36/37-39
• WGK Germany: 3
• HazardClass: IRRITANT
• Hazardous Substances Data: 79762-54-2(Hazardous Substances Data)

Usage

Uses

6-Bromo-1H-indazole is an indazole derivative being studied as an inhibitor of DNA gyrase B and its antibacterial activity.

Upstream product

• 57848-46-1 4-bromo-2-fluorobenzaldehyde 
• 6967-12-0 6-amino-1H-indazole 
• 593-56-6 N-methoxylamine hydrochloride 
• 93777-26-5 5-bromo-2-fluorobenzaldehyde 
• 651780-33-5 1-(6-bromo-1H-indazol-1-yl)ethanone 
• 12775-96-1 copper 
• 39478-78-9 5-bromo-2-methylaniline 

Downstream Products

• 1049651-40-2 1-(4-methoxybenzyl)-6-bromo-1H-indazole 
• 669050-69-5 1H-indazole-6-carboxyaldehyde 
• 1204400-68-9 C₁₅H₁₇N₃O₂ 
• 1248590-87-5 N-(pyridin-2-yl)-1H-indazol-6-amine 
• 1248590-80-8 4-(4-chlorophenyl)-1-(1H-indazol-6-yl)piperidin-4-ol 
• 1248590-82-0 N-isopropyl-N-phenyl-1H-indazol-6-amine 
• 1248590-81-9 N-(3-fluorophenyl)-N-methyl-1H-indazol-6-amine 
• 1248590-79-5 N-benzyl-N-ethyl-1H-indazol-6-amine 
• 1248590-88-6 N₁-(1H-indazol-6-yl)-N₂,N₂-dimethylethane-1,2-diamine 
• 1426095-02-4 N-{[(3S)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4-(1H-indazol-6-yl)-N-methylbenzamide 
• 1426095-23-9 N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-N-ethyl-4-(1H-indazyl)benzamide 
• 1426095-27-3 N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4-(1H-indazol-6-yl)-N-(1-methylethyl)benzamide 
• 1426095-38-6 N-{[(3R)-1-cyclopropylcarbonyl-3-pyrrolidinyl]methyl}-4-(1H-indazol-6-yl)-N-(phenylmethyl)benzamide 
• 1426845-58-0 6-bromo-1-(4-fluorophenyl)-1H-indazole 

Relevant articles and documents

Compound with AMPK agonistic activity and preparation and application of prodrug thereof

The invention relates to a compound with AMPK agonistic activity and a prodrug thereof, and as well as a preparation method and medical application of a prodrug thereof. The compound has the structure shown in the formula (I), and the prodrug of the compound has the structure shown in the formula (II), wherein each group and the substituent are as defined in the specification. The invention discloses a preparation method of the compound and application of the compound in prevention and treatment AMPK related diseases, and the AMPK related diseases include, but are not limited to, energy metabolism abnormality related diseases. Neurodegenerative diseases and inflammation-related diseases and the like.

TYK2 INHIBITORS AND USES THEREOF

The present invention provides compounds, compositions thereof, and methods of using the same for the inhibition of TYK2, and the treatment of TYK2-mediated disorders.

Discovery of 4-Aminoquinoline-3-carboxamide derivatives as potent reversible Bruton's tyrosine kinase inhibitors for the treatment of rheumatoid arthritis

A structure-hopping strategy was applied to discover a series of novel 4-aminoquinoline-3-carboxamide derivatives as potent, reversible BTK inhibitors. Compared to the previously described cinnoline scaffold compounds, the 4-aminoquinoline analogues showed significantly improved drug-like properties, especially in their aqueous solubility. The most potent compound, 25, displayed a stronger inhibitory effect on both BTKWT (IC50 = 5.3 nM) and BTKC481S (IC50 = 39 nM). In a rodent collagen-induced arthritis model, compound 25 efficiently reduced paw swelling without a loss in body weight. On the basis of potency, drug-like properties, stability, and noncovalent mode of inhibition, our representative inhibitors could have a promising profile to be treatments for a wide range of autoimmune diseases.